As of 2025-05-20, the Intrinsic Value of Korea United Pharm Inc (033270.KS) is 11,920.27 KRW. This 033270.KS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 19,000.00 KRW, the upside of Korea United Pharm Inc is -37.30%.
The range of the Intrinsic Value is 9,580.38 - 16,586.16 KRW
Based on its market price of 19,000.00 KRW and our intrinsic valuation, Korea United Pharm Inc (033270.KS) is overvalued by 37.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 9,580.38 - 16,586.16 | 11,920.27 | -37.3% |
| DCF (Growth 10y) | 13,093.01 - 22,663.08 | 16,311.51 | -14.1% |
| DCF (EBITDA 5y) | 19,243.97 - 37,028.79 | 22,106.40 | 16.3% |
| DCF (EBITDA 10y) | 20,677.20 - 40,087.15 | 24,239.76 | 27.6% |
| Fair Value | 10,177.70 - 10,177.70 | 10,177.70 | -46.43% |
| P/E | 30,979.69 - 50,478.03 | 44,162.91 | 132.4% |
| EV/EBITDA | 17,747.77 - 44,273.60 | 22,214.57 | 16.9% |
| EPV | 21,305.72 - 27,024.90 | 24,165.34 | 27.2% |
| DDM - Stable | 16,913.92 - 42,944.69 | 29,929.33 | 57.5% |
| DDM - Multi | 26,233.38 - 51,182.42 | 34,628.90 | 82.3% |
| Market Cap (mil) | 310,270.00 |
| Beta | 0.57 |
| Outstanding shares (mil) | 16.33 |
| Enterprise Value (mil) | 292,215.40 |
| Market risk premium | 5.82% |
| Cost of Equity | 8.19% |
| Cost of Debt | 4.25% |
| WACC | 7.96% |